Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Senior VP and General Counsel

Sr VP, Technical Ops

SVP, CFO and Secretary

Chief Operating Officer

Sr VP, Research & CSO

President and CEO

VP, Controller and Treasurer

Chief Medical Officer

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 Ãƒâ€” CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ãƒâ€” CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United Stat...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-04	Premium	sold	Premium	Premium	Premium	Senior VP and General Counsel
2024-04-04	Premium	acquired	Premium	Premium	Premium	Senior VP and General Counsel
2024-03-06	Premium	acquired	Premium	Premium	Premium	Senior VP and General Counsel
2024-03-06	Premium	sold	Premium	Premium	Premium	Senior VP and General Counsel
2024-03-04	Premium	acquired	Premium	Premium	Premium	Sr VP, Technical Ops
2024-03-04	Premium	sold	Premium	Premium	Premium	SVP, CFO and Secretary
2024-03-04	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-03-04	Premium	sold	Premium	Premium	Premium	Sr VP, Technical Ops
2024-02-26	Premium	sold	Premium	Premium	Premium	Senior VP and General Counsel
2024-02-22	Premium	acquired	Premium	Premium	Premium	Senior VP and General Counsel
2024-02-22	Premium	sold (taxes)	Premium	Premium	Premium	Sr VP, Research & CSO
2024-02-22	Premium	sold (taxes)	Premium	Premium	Premium	Senior VP and General Counsel
2024-02-22	Premium	acquired	Premium	Premium	Premium	Sr VP, Research & CSO
2024-02-15	Premium	acquired	Premium	Premium	Premium	Senior VP and General Counsel
2024-02-15	Premium	acquired	Premium	Premium	Premium	Sr VP, Technical Ops
2024-02-15	Premium	acquired	Premium	Premium	Premium	Sr VP, Research & CSO
2024-02-15	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	VP, Controller and Treasurer
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2024-02-15	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	Sr VP, Research & CSO
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	Sr VP, Technical Ops
2024-02-15	Premium	acquired	Premium	Premium	Premium	SVP, CFO and Secretary
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	SVP, CFO and Secretary

MGNX - MacroGenics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for MGNX